| |
The Lilly MDR-TB Partnership is a public-private initiative wholly funded by the Eli Lilly and Company Foundation to address the expanding crisis of multidrug-resistant tuberculosis (MDR-TB).
The partnership is pursuing a comprehensive strategy to fight
MDR-TB by providing access to medicines, transferring manufacturing
technology, training healthcare workers, raising awareness of
the disease and providing resources for prevention, diagnosis
and treatment of people living with MDR-TB. |
|
Africa's largest pharmaceutical manufacturer
and the technology transfer partner in South Africa, Aspen Pharmacare
produces both cycloserine and capreomycin for the treatment of
MDR-TB. Aspen sold its first batch of cycloserine in 2006 and
is now producing cycloserine at a newly constructed facility in
Port Elizabeth, South Africa. It will commence the commercial
manufacturing of capreomycin at this facility in 2009.
www.aspenpharma.com
|
|
Eli Lilly and Company, a leading innovation-driven
corporation, is developing a growing portfolio of first-in-class
and best-in-class pharmaceutical products by applying the latest
research from its own worldwide laboratories and from collaborations
with eminent scientific organizations. Headquartered in Indianapolis,
USA, Lilly provides answers -- through medicines and information
-- for some of the world's most urgent medical needs.
Additional information about Lilly is available at http://www.lilly.com
|
|
Harvard University and the nonprofit, Partners
in Health, have established a Center of Excellence for MDR-TB
treatment and training in Tomsk, Russia, where several hundred
doctors, nurses and health care workers from cities all over Russia
and the former Soviet Union have been trained in the prevention,
detection and treatment of MDR-TB.
www.pih.org
|
|
| One of the largest bulk active pharmaceutical
ingredient (API) manufacturers in China, Hisun is a Lilly transfer
of technology partner. Hisun produced its first batch of the active
ingredient for capreomycin in 2006 and is currently building a
facility to manufacture the capreomycin final product.
www.hisunpharm.com
|
|
|
A federation of national associations representing
nurses in more than 130 countries, ICN has launched a global project
to equip nurses with the knowledge and tools for detection, treatment
and management of TB/MDR-TB. ICN has published a set of guidelines
and has established an online "Global TB/MDR-TB Resource
Centre" for 13 million nurses working worldwide. In
2005, ICN launched its first TB/MDR-TB Train-the-Trainer program
for nurses in South Africa and the Philippines. ICN is also implementing
the program in Angola, Kenya, Lesotho, Malawi, Mozambique, Russia,
Swaziland and Uganda.
www.icn.ch
|
|
The world's largest humanitarian organization,
IFRC has implemented TB-patient support programs aimed at the
most vulnerable populations, including homeless people and those
suffering from alcoholism and drug addiction. These programs include
public awareness and anti-stigma campaigns, community outreach,
psychological support and food aid. IFRC has started expanding
its activities in more than 14 countries, including Kazakhstan,
Romania and Uzbekistan.
www.ifrc.org
|
|
The International Hospital Federation (IHF),
a non-governmental organization, has developed a comprehensive
TB and MDR-TB-control training manual for hospital managers that
is available to its membership network of some 40,000 public and
private hospitals and clinics in some 100 countries. The goal
of the manual is to provide health care facility and hospital
managers with an overview of the basics of TB control together
with the appropriate expertise and necessary resources, to clarify
the roles and skills they need to enable them to make informed
decisions about the management of TB patients and participate
effectively in developing and maintaining a successful and sustainable
TB and MDR-TB control programme in their facilities. The manual,
which was pilot-tested in South Africa in 2006, will also serve
as a valuable guide for infection control for patients and staff,
helping to fight a growing health threat in hospitals and clinics
in developing countries.
www.ihf-fih.org
|
|
|
Purdue University has been assisting in the
transfer of technology by training partner companies in Good Manufacturing
Practices. The Chao Center for Industrial Pharmacy and Contract
Manufacturing is a cGMP pharmaceutical manufacturer owned by Purdue
Research Foundation and is active in the manufacturing of drug
and placebo for clinical trials, formulation development, analytical
support and consulting on regulatory compliance. The Chao Center
will manufacture Seromycin for the United States and to Canada.
www.purdue.edu
www.thechaocenter.com
|
|
is a nonprofit grassroots advocacy organization
committed to creating the political will to end hunger and the
worst aspects of poverty. Working with activists in the U.S. and
in affected countries around the world, RESULTS advocates for
increased resources and action to stop TB.
www.results.org
|
|
| An API manufacturer and the technology transfer
partner in India, Shasun dispatched its first order for the active
ingredient of cycloserine in 2006 to Aspen Pharmacare, which formulates
the finished product. Shasun received registration approval for
the cycloserine active ingredient in the UK and is working with
Purdue University to gain FDA Approval, which is expected by mid
2009. Shasun also has partnered with a local hospital and Rotary
International to develop a TB screening program.
www.shasun.com
|
|
One of Russia's largest pharmaceutical companies
and Lilly's newest technology transfer partner (since 2006), SIA
will start producing cycloserine in 2008 and package capastat
in 2009/2010.
|
|
|
The Stop TB Partnership was established in
2000 to realize the goal of eliminating TB as a public health
problem and, ultimately, to obtain a world free of TB. It comprises
a network of international organizations, countries, donors from
the public and private sectors, governmental and nongovernmental
organizations and individuals that have expressed an interest
in working together to achieve this goal. Stop TB has launched
an award for reporting on TB and is leading a global campaign
featuring well known Stop TB Ambassadors to raise awareness on
the disease.
http://www.stoptb.org
http://www.stoptb.org/figo
|
|
TB Alert is the only British nonprofit working
solely on fighting TB in the UK and overseas. It was set up by
people who felt that with its long tradition of TB work, there
should be a greater response in Britain to the resurgent threat
of tuberculosis - already declared a global emergency by the World
Health Organisation (WHO) in 1993. TB Alert has developed leaflets
for patients with MDR-TB and is implementing a project for the
training of community volunteers in slums in India.
www.tbalert.org
|
The Advocacy Partnership is going to play
an active role in raising awareness about TB and MDR-TB. It circulates
country-specific information about TB/MDR-TB, publishes self-help
materials and offers one-to-one patient mentoring through its
Tuberculosis Survival Project website.
www.tbsurvivalproject.org |
|
|
Part of the U.S. Department of Health and
Human Services, the CDC has developed a cutting-edge laboratory
information management system for MDR-TB, which will be implemented
in Russia. This new system will enable counting, monitoring and
reporting of confirmed TB cases, including drug-resistant strains,
more quickly, easily and accurately than with traditional methods.
www.cdc.gov
|
|
An independent organization representing
the world's 1,000 leading companies, WEF is committed to improving
the state of the world by engaging leaders in partnerships that
shape global, regional and private sector agendas. The WEF has
developed a TB and MDR-TB Toolkit for the Workplace, which has
been distributed in India, and is working in adapting it for South
Africa and China.
www.weforum.org
|
|
WHO is the directing and coordinating authority
for health within the United Nations system. The WHO provides
technical support to countries to set up policies and programs
for prevention and control of MDR-TB, and supports training on
MDR-TB management. WHO also supports drug resistance surveillance
and laboratory strengthening, as well as the implementation of
new tools for recording and reporting purposes.
www.who.int
|
|
The World Medical Association (WMA) is the
independent confederation of national medical associations from
more than 80 countries and represents more than eight million
physicians. Acting on behalf of patients and physicians, the WMA
endeavours to achieve the highest possible standards of medical
care, ethics, education and health-related human rights for all
people. The WMA is developing a free, web-based MDR-TB self-study
course for physicians. The online course will provide access to
the latest international protocols for MDR-TB prevention, treatment
and management. WMA is also active in the provision of training
and is developing a declaration on ethics in TB.
www.wma.net |
|
|
PARTNERS